AI has accelerated drug discovery, but it has also shortened the window of competitive advantage. This article explores why patent strategy must evolve beyond protecting individual molecules to safeguarding the platforms, data, and infrastructure that create long-term business value.

Owning a patented molecule does not necessarily mean owning the innovation behind it. As AI transforms drug discovery, companies must understand how data, platforms, collaborations, and IP agreements shape long-term ownership, commercialization, and competitive advantage.

Explore Hylton-Rodic Law’s Q2 2026 highlights, including our new Adams Morgan office, AI patent strategy discussions, industry events, educational programming, and continued growth serving innovators in life sciences and technology.

AI is accelerating drug discovery and compressing the timeline for critical intellectual property decisions. This article explores how biotech and pharmaceutical companies can build stronger patent strategies, documentation practices, and decision frameworks to protect innovation and long-term enterprise value.

As innovation accelerates, life sciences companies must align patent strategy with long-term growth. This update explores how portfolio design, operational structure, and early IP decisions shape flexibility, commercialization, and long-term value.

As billions in drug patents expire, the pharmaceutical industry faces a looming patent cliff. Biotech innovators must rethink IP protection to safeguard revenue and innovation. This article explores trade secrets, continuous filings, data ownership, and regulatory exclusivity, strategies that help companies adapt and thrive beyond patent loss.